NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Formats Text Remove constraint Formats: Text Languages English Remove constraint Languages: English Copyright Public domain Remove constraint Copyright: Public domain

Search Results

52. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

53. Medicare payments for clinical diagnostic laboratory tests in 2016: year 3 of baseline data

54. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

55. Medicaid Fraud Control Units: investigation and prosecution of fraud and beneficiary abuse in Medicaid personal care services

56. Followup review: CMS's management of the quality payment program

57. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

58. Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC

59. Drug supply chain security: dispensers received most tracing information

61. Round two competitive bidding for oxygen: continued access for vast majority of beneficiaries

62. Round two competitive bidding for enteral nutrition: continued access for vast majority of beneficiaries

63. HRSA helped health centers with elevated risks and can continue to take additional steps

65. Part D plans generally include drugs commonly used by dual eligibles: 2018

67. Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness

68. Opioid use in Medicare Part D remains concerning

69. CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities

70. Opioids in Ohio Medicaid: review of extreme use and prescribing

73. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

74. Questionable billing for compounded topical drugs in Medicare Part D

75. FDA should further integrate its review of cybersecurity into the premarket review process for medical devices

76. Treatment planning and medication monitoring were lacking for children in foster care receiving psychotropic medication

77. Medicare payments for clinical diagnostic laboratory tests in 2017: year 4 of baseline data

81. Medicare Advantage appeal outcomes and audit findings raise concerns about service and payment denials

82. States follow a common framework in responding to breaches of Medicaid data

83. Hospitals reported improved preparedness for emerging infectious diseases after the Ebola outbreak

85. Possible higher spending paths for veterans' benefits